ID   HTSF1_HUMAN             Reviewed;         755 AA.
AC   O43719; D3DWG9; Q59G06; Q99730;
DT   05-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   28-JUN-2023, entry version 199.
DE   RecName: Full=HIV Tat-specific factor 1;
DE            Short=Tat-SF1;
GN   Name=HTATSF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 26-45; 62-79; 155-169;
RP   199-210; 239-245 AND 410-428, FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Promyelocytic leukemia;
RX   PubMed=8849451; DOI=10.1126/science.274.5287.605;
RA   Zhou Q., Sharp P.A.;
RT   "Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1
RT   Tat.";
RL   Science 274:605-610(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-478.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Choriocarcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH CDK9.
RX   PubMed=9649438; DOI=10.1093/emboj/17.13.3681;
RA   Zhou Q., Chen D., Pierstorff E., Luo K.;
RT   "Transcription elongation factor P-TEFb mediates Tat activation of HIV-1
RT   transcription at multiple stages.";
RL   EMBO J. 17:3681-3691(1998).
RN   [8]
RP   FUNCTION.
RX   PubMed=9765201; DOI=10.1101/gad.12.19.2992;
RA   Li X.-Y., Green M.R.;
RT   "The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription
RT   elongation factor.";
RL   Genes Dev. 12:2992-2996(1998).
RN   [9]
RP   INTERACTION WITH SF3A2.
RX   PubMed=9710584; DOI=10.1128/mcb.18.9.5000;
RA   Yan D., Perriman R., Igel H., Howe K.J., Neville M., Ares M. Jr.;
RT   "CUS2, a yeast homolog of human Tat-SF1, rescues function of misfolded U2
RT   through an unusual RNA recognition motif.";
RL   Mol. Cell. Biol. 18:5000-5009(1998).
RN   [10]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH NCL; CCNT1; RNA POLYMERASE
RP   II; SUPT5H AND CDK9.
RX   PubMed=10393184; DOI=10.1093/emboj/18.13.3688;
RA   Parada C.A., Roeder R.G.;
RT   "A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-
RT   1 transcription.";
RL   EMBO J. 18:3688-3701(1999).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH GTF2F2; SUPT5H AND POLR2A.
RX   PubMed=10454543; DOI=10.1128/mcb.19.9.5960;
RA   Kim J.B., Yamaguchi Y., Wada T., Handa H., Sharp P.A.;
RT   "Tat-SF1 protein associates with RAP30 and human SPT5 proteins.";
RL   Mol. Cell. Biol. 19:5960-5968(1999).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH CCNT1.
RX   PubMed=10913173; DOI=10.1128/mcb.20.16.5897-5907.2000;
RA   Fong Y.W., Zhou Q.;
RT   "Relief of two built-In autoinhibitory mechanisms in P-TEFb is required for
RT   assembly of a multicomponent transcription elongation complex at the human
RT   immunodeficiency virus type 1 promoter.";
RL   Mol. Cell. Biol. 20:5897-5907(2000).
RN   [13]
RP   FUNCTION.
RX   PubMed=11420046; DOI=10.1016/s1074-7613(01)00158-3;
RA   Simmons A., Aluvihare V., McMichael A.;
RT   "Nef triggers a transcriptional program in T cells imitating single-signal
RT   T cell activation and inducing HIV virulence mediators.";
RL   Immunity 14:763-777(2001).
RN   [14]
RP   FUNCTION, MUTAGENESIS OF TYR-136, INTERACTION WITH U SNRNPS AND CCNT1, AND
RP   DOMAIN.
RX   PubMed=11780068; DOI=10.1038/414929a;
RA   Fong Y.W., Zhou Q.;
RT   "Stimulatory effect of splicing factors on transcriptional elongation.";
RL   Nature 414:929-933(2001).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH TCERG1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15485897; DOI=10.1128/mcb.24.21.9274-9285.2004;
RA   Smith M.J., Kulkarni S., Pawson T.;
RT   "FF domains of CA150 bind transcription and splicing factors through
RT   multiple weak interactions.";
RL   Mol. Cell. Biol. 24:9274-9285(2004).
RN   [16]
RP   FUNCTION.
RX   PubMed=15905670; DOI=10.1097/01.aids.0000171403.07995.92;
RA   Misse D., Gajardo J., Oblet C., Religa A., Riquet N., Mathieu D., Yssel H.,
RA   Veas F.;
RT   "Soluble HIV-1 gp120 enhances HIV-1 replication in non-dividing CD4+ T
RT   cells, mediated via cell signaling and Tat cofactor overexpression.";
RL   AIDS 19:897-905(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-498; SER-557; SER-561;
RP   SER-579; SER-597; SER-600; SER-616; SER-624; SER-642; SER-676; SER-702;
RP   SER-713 AND SER-714, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452; SER-453; SER-498;
RP   SER-642; SER-713 AND SER-714, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-579; SER-616; SER-624;
RP   SER-642 AND SER-676, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-642; SER-702; SER-713 AND
RP   SER-714, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387; SER-403; SER-407;
RP   SER-445; SER-498; SER-579; SER-616; SER-624; THR-633; SER-642; SER-676;
RP   SER-702; SER-713; SER-714 AND SER-721, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387; SER-485; SER-579;
RP   SER-597; SER-600; SER-607; SER-616; SER-642; SER-676; SER-702; SER-713;
RP   SER-714 AND SER-721, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-445; SER-481; SER-494;
RP   SER-498; SER-521; SER-529; SER-579; SER-616; SER-624; SER-642; SER-676;
RP   SER-702; SER-713; SER-714 AND SER-721, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-579; SER-642 AND SER-702, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-429 AND LYS-430, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [30]
RP   STRUCTURE BY NMR OF 256-354.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RRM_1 domain of HIV Tat specific factor 1
RT   variant.";
RL   Submitted (SEP-2006) to the PDB data bank.
CC   -!- FUNCTION: Functions as a general transcription factor playing a role in
CC       the process of transcriptional elongation. May mediate the reciprocal
CC       stimulatory effect of splicing on transcriptional elongation. In case
CC       of infection by HIV-1, it is up-regulated by the HIV-1 proteins NEF and
CC       gp120, acts as a cofactor required for the Tat-enhanced transcription
CC       of the virus. {ECO:0000269|PubMed:10393184,
CC       ECO:0000269|PubMed:10454543, ECO:0000269|PubMed:10913173,
CC       ECO:0000269|PubMed:11420046, ECO:0000269|PubMed:11780068,
CC       ECO:0000269|PubMed:15905670, ECO:0000269|PubMed:8849451,
CC       ECO:0000269|PubMed:9765201}.
CC   -!- SUBUNIT: Component of a complex which is at least composed of
CC       HTATSF1/Tat-SF1, the P-TEFb complex components CDK9 and CCNT1, RNA
CC       polymerase II, SUPT5H, and NCL/nucleolin. Interacts with GTF2F2/RAP30
CC       and POLR2A. Interacts with TCERG1/CA150. Interacts with SF3A2/SAP62 and
CC       the spliceosomal U small nuclear ribonucleoproteins (snRNPs).
CC       {ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10454543,
CC       ECO:0000269|PubMed:10913173, ECO:0000269|PubMed:11780068,
CC       ECO:0000269|PubMed:15485897, ECO:0000269|PubMed:9649438,
CC       ECO:0000269|PubMed:9710584}.
CC   -!- INTERACTION:
CC       O43719; O75533-1: SF3B1; NbExp=6; IntAct=EBI-720468, EBI-15565798;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15485897,
CC       ECO:0000269|PubMed:8849451}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:8849451}.
CC   -!- DOMAIN: The RRM domains mediate interaction with U snRNPs.
CC       {ECO:0000269|PubMed:11780068}.
CC   -!- SIMILARITY: Belongs to the HTATSF1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18823.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAD92540.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U76992; AAB18823.1; ALT_FRAME; mRNA.
DR   EMBL; BT006886; AAP35532.1; -; mRNA.
DR   EMBL; AB209303; BAD92540.1; ALT_INIT; mRNA.
DR   EMBL; Z97632; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471150; EAW88468.1; -; Genomic_DNA.
DR   EMBL; CH471150; EAW88469.1; -; Genomic_DNA.
DR   EMBL; BC009896; AAH09896.1; -; mRNA.
DR   CCDS; CCDS14657.1; -.
DR   RefSeq; NP_001156752.1; NM_001163280.1.
DR   RefSeq; NP_055315.2; NM_014500.4.
DR   RefSeq; XP_005262461.1; XM_005262404.3.
DR   PDB; 2DIT; NMR; -; A=256-354.
DR   PDB; 6N3D; X-ray; 1.13 A; A=260-353.
DR   PDB; 6N3E; X-ray; 1.89 A; A=260-353.
DR   PDB; 6N3F; X-ray; 2.10 A; A/C=260-353.
DR   PDB; 6NSX; X-ray; 2.00 A; A=260-353.
DR   PDB; 6Y50; EM; 4.10 A; q=1-755.
DR   PDB; 6Y53; EM; 7.10 A; q=1-755.
DR   PDB; 6Y5Q; EM; 7.10 A; q=1-755.
DR   PDB; 7EVO; EM; 2.50 A; D=1-755.
DR   PDB; 7Q3L; EM; 2.30 A; q=2-755.
DR   PDB; 8HK1; EM; 2.70 A; D=1-755.
DR   PDBsum; 2DIT; -.
DR   PDBsum; 6N3D; -.
DR   PDBsum; 6N3E; -.
DR   PDBsum; 6N3F; -.
DR   PDBsum; 6NSX; -.
DR   PDBsum; 6Y50; -.
DR   PDBsum; 6Y53; -.
DR   PDBsum; 6Y5Q; -.
DR   PDBsum; 7EVO; -.
DR   PDBsum; 7Q3L; -.
DR   PDBsum; 8HK1; -.
DR   AlphaFoldDB; O43719; -.
DR   SMR; O43719; -.
DR   BioGRID; 118149; 135.
DR   ComplexPortal; CPX-2539; U2 small nuclear ribonucleoprotein complex.
DR   CORUM; O43719; -.
DR   DIP; DIP-42095N; -.
DR   IntAct; O43719; 46.
DR   MINT; O43719; -.
DR   STRING; 9606.ENSP00000442699; -.
DR   GlyGen; O43719; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O43719; -.
DR   MetOSite; O43719; -.
DR   PhosphoSitePlus; O43719; -.
DR   BioMuta; HTATSF1; -.
DR   EPD; O43719; -.
DR   jPOST; O43719; -.
DR   MassIVE; O43719; -.
DR   MaxQB; O43719; -.
DR   PaxDb; O43719; -.
DR   PeptideAtlas; O43719; -.
DR   ProteomicsDB; 49133; -.
DR   Antibodypedia; 375; 314 antibodies from 35 providers.
DR   DNASU; 27336; -.
DR   Ensembl; ENST00000218364.5; ENSP00000218364.4; ENSG00000102241.12.
DR   Ensembl; ENST00000535601.5; ENSP00000442699.1; ENSG00000102241.12.
DR   GeneID; 27336; -.
DR   KEGG; hsa:27336; -.
DR   MANE-Select; ENST00000218364.5; ENSP00000218364.4; NM_014500.5; NP_055315.2.
DR   UCSC; uc004ezw.4; human.
DR   AGR; HGNC:5276; -.
DR   CTD; 27336; -.
DR   GeneCards; HTATSF1; -.
DR   HGNC; HGNC:5276; HTATSF1.
DR   HPA; ENSG00000102241; Low tissue specificity.
DR   MIM; 300346; gene.
DR   neXtProt; NX_O43719; -.
DR   OpenTargets; ENSG00000102241; -.
DR   PharmGKB; PA29540; -.
DR   VEuPathDB; HostDB:ENSG00000102241; -.
DR   eggNOG; KOG1548; Eukaryota.
DR   GeneTree; ENSGT00390000009902; -.
DR   HOGENOM; CLU_406872_0_0_1; -.
DR   InParanoid; O43719; -.
DR   OMA; RIRHFSE; -.
DR   OrthoDB; 10213at2759; -.
DR   PhylomeDB; O43719; -.
DR   TreeFam; TF313623; -.
DR   PathwayCommons; O43719; -.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   SignaLink; O43719; -.
DR   SIGNOR; O43719; -.
DR   BioGRID-ORCS; 27336; 371 hits in 788 CRISPR screens.
DR   ChiTaRS; HTATSF1; human.
DR   EvolutionaryTrace; O43719; -.
DR   GeneWiki; HTATSF1; -.
DR   GenomeRNAi; 27336; -.
DR   Pharos; O43719; Tbio.
DR   PRO; PR:O43719; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O43719; protein.
DR   Bgee; ENSG00000102241; Expressed in sural nerve and 216 other tissues.
DR   ExpressionAtlas; O43719; baseline and differential.
DR   Genevisible; O43719; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005681; C:spliceosomal complex; NAS:ComplexPortal.
DR   GO; GO:0005686; C:U2 snRNP; IBA:GO_Central.
DR   GO; GO:0005684; C:U2-type spliceosomal complex; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; NAS:ComplexPortal.
DR   GO; GO:0032784; P:regulation of DNA-templated transcription elongation; TAS:ProtInc.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:1903241; P:U2-type prespliceosome assembly; NAS:ComplexPortal.
DR   GO; GO:0019079; P:viral genome replication; TAS:ProtInc.
DR   CDD; cd12281; RRM1_TatSF1_like; 1.
DR   CDD; cd12282; RRM2_TatSF1_like; 1.
DR   Gene3D; 3.30.70.330; -; 2.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR034393; TatSF1-like.
DR   InterPro; IPR034392; TatSF1-like_RRM1.
DR   PANTHER; PTHR15608:SF0; HIV TAT-SPECIFIC FACTOR 1; 1.
DR   PANTHER; PTHR15608; SPLICING FACTOR U2AF-ASSOCIATED PROTEIN 2; 1.
DR   Pfam; PF00076; RRM_1; 2.
DR   SMART; SM00360; RRM; 2.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 1.
DR   PROSITE; PS50102; RRM; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Direct protein sequencing;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   RNA-binding; Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..755
FT                   /note="HIV Tat-specific factor 1"
FT                   /id="PRO_0000248604"
FT   DOMAIN          133..218
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          264..349
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          1..53
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          81..122
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          380..415
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          381..755
FT                   /note="Mediates interaction with the P-TEFb complex"
FT   REGION          433..755
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        10..33
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        92..122
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        433..473
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        488..534
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        535..549
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        550..593
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        594..651
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        652..669
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        670..717
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   MOD_RES         297
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BGC0"
FT   MOD_RES         387
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         403
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         409
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BGC0"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         453
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         481
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         485
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         494
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         557
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         561
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         579
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         597
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         600
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         607
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         616
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         633
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         642
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         676
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         702
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         713
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         714
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         721
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   CROSSLNK        429
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        430
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         478
FT                   /note="G -> A (in dbSNP:rs2071913)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_027362"
FT   VARIANT         526
FT                   /note="N -> T (in dbSNP:rs12852634)"
FT                   /id="VAR_052206"
FT   VARIANT         678
FT                   /note="D -> G (in dbSNP:rs17339410)"
FT                   /id="VAR_052207"
FT   MUTAGEN         136
FT                   /note="Y->D: Loss of interaction with U snRNPs."
FT                   /evidence="ECO:0000269|PubMed:11780068"
FT   CONFLICT        125
FT                   /note="F -> V (in Ref. 3; BAD92540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        587
FT                   /note="V -> I (in Ref. 3; BAD92540)"
FT                   /evidence="ECO:0000305"
FT   STRAND          134..139
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   HELIX           146..154
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   STRAND          165..174
FT                   /evidence="ECO:0007829|PDB:7EVO"
FT   STRAND          176..178
FT                   /evidence="ECO:0007829|PDB:7EVO"
FT   STRAND          185..190
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   HELIX           192..200
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   TURN            201..203
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   HELIX           241..244
FT                   /evidence="ECO:0007829|PDB:7Q3L"
FT   HELIX           261..264
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   STRAND          265..269
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   HELIX           274..277
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   HELIX           282..295
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   TURN            296..298
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   STRAND          301..306
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   STRAND          315..321
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   HELIX           322..332
FT                   /evidence="ECO:0007829|PDB:6N3D"
FT   STRAND          343..346
FT                   /evidence="ECO:0007829|PDB:6N3D"
SQ   SEQUENCE   755 AA;  85853 MW;  C9CA6C89E4F2A319 CRC64;
     MSGTNLDGND EFDEQLRMQE LYGDGKDGDT QTDAGGEPDS LGQQPTDTPY EWDLDKKAWF
     PKITEDFIAT YQANYGFSND GASSSTANVE DVHARTAEEP PQEKAPEPTD ARKKGEKRKA
     ESGWFHVEED RNTNVYVSGL PPDITVDEFI QLMSKFGIIM RDPQTEEFKV KLYKDNQGNL
     KGDGLCCYLK RESVELALKL LDEDEIRGYK LHVEVAKFQL KGEYDASKKK KKCKDYKKKL
     SMQQKQLDWR PERRAGPSRM RHERVVIIKN MFHPMDFEDD PLVLNEIRED LRVECSKFGQ
     IRKLLLFDRH PDGVASVSFR DPEEADYCIQ TLDGRWFGGR QITAQAWDGT TDYQVEETSR
     EREERLRGWE AFLNAPEANR GLRRSDSVSA SERAGPSRAR HFSEHPSTSK MNAQETATGM
     AFEEPIDEKK FEKTEDGGEF EEGASENNAK ESSPEKEAEE GCPEKESEEG CPKRGFEGSC
     SQKESEEGNP VRGSEEDSPK KESKKKTLKN DCEENGLAKE SEDDLNKESE EEVGPTKESE
     EDDSEKESDE DCSEKQSEDG SEREFEENGL EKDLDEEGSE KELHENVLDK ELEENDSENS
     EFEDDGSEKV LDEEGSEREF DEDSDEKEEE EDTYEKVFDD ESDEKEDEEY ADEKGLEAAD
     KKAEEGDADE KLFEESDDKE DEDADGKEVE DADEKLFEDD DSNEKLFDEE EDSSEKLFDD
     SDERGTLGGF GSVEEGPLST GSSFILSSDD DDDDI
//
